Sue Sutter | News, Articles and Opinions | Xconomy

Sue Sutter

Sue is a senior editor with Pink Sheet, where she writes primarily about drug, biologic and biosimilar regulation, FDA advisory committees and product approvals.

Recent posts

Biogen’s AdComm Meeting Will Test FDA’s “Substantial Evidence” Flexibility
A US Food and Drug Administration advisory committee meeting on Biogen, Inc.’s Alzheimer’s drug aducanumab will offer some insight into the amount of flexibility the agency and its external experts are... Read more »
Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations
Gene therapy product developers are seeking more clarity from the US Food and Drug Administration on when viral vectors from the same class will be considered sufficiently different for purposes of... Read more »

Page 1 of 1

Underwriters and Partners

Xconomy Insight

Sponsored · Special Report
As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future
Hyperinflation in rents is over
Hughes Marino

Sponsored · Whitepaper
How Healthy Are Your Market Access Programs?
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Archbow Consulting

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

Xconomy on Demand

We offer a number of ways to subscribe for free!